From Pulse 2.0 · Amit Chowdhry · · 1m 20s
Pfizer and Blackstone Secure $1.5 Billion for Obesity Drug
Pfizer and Blackstone Life Sciences agree to fund berobenatide's development up to $1.5 billion by 2028.
In brief
Pfizer and Blackstone Life Sciences agree to fund berobenatide's development up to $1.5 billion by 2028. Pfizer secured $1.5 billion in funding from Blackstone Life Sciences to advance its monthly GLP-1 obesity drug berobenatide through 2028. Originally reported by Pulse 2.0.
Funding Agreement Details
Pfizer and Blackstone Life Sciences entered a strategic funding agreement for up to $1.5 billion through 2028 to support berobenatide's clinical development.
Funding Structure
Blackstone will receive milestone payments tied to U.S. regulatory approval and commercial sales targets for berobenatide.
Berobenatide Overview
Berobenatide is an investigational monthly GLP-1 receptor agonist peptide for chronic weight management and obesity-related conditions.
Clinical Development Plan
Pfizer plans over 20 clinical trials in 2026, including 10 Phase 3 trials for berobenatide's safety and effectiveness.
Cardiometabolic Focus
Pfizer positions berobenatide as a key treatment for knee osteoarthritis and obstructive sleep apnea alongside weight management.
Blackstone's Role
Blackstone Life Sciences provides $18 billion in assets to support pharmaceutical research through milestone-based investments.
Milestone Payments
Blackstone earns payments if berobenatide gets U.S. regulatory approval and meets sales targets for chronic weight management.
Ownership and Control
Pfizer retains full control over berobenatide's clinical development and decision-making without selling ownership.
Next Steps
Pfizer aims to accelerate cardiometabolic research while maintaining financial flexibility through 2028.
The big picture
Pfizer secured $1.5 billion in funding from Blackstone Life Sciences to advance its monthly GLP-1 obesity drug berobenatide through 2028.
